NEWS DESK

AXS Stock News, News Score & What It Could Mean

Axis Capital Holdings Limited Common Stock (AXS) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.

HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$110.71
Trend Context
Mixed / range
Latest briefing

What's happening with AXS

globenewswire.com15 Jul 2026

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com6 Jul 2026

AXIS Capital to Release Second Quarter Financial Results on July 28, 2026

PEMBROKE, Bermuda, July 06, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2026 on Tuesday, July 28, 2026 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Matthew Kirk, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 29, 2026 at 8:30 a.m.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com15 Jun 2026

AXIS Appoints Pradip Patiath to Its Board of Directors

PEMBROKE, Bermuda, June 15, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) today announced that it has appointed Pradip Patiath to the Company's Board of Directors. Effective June 15, 2026, Mr. Patiath will join the Board, where he will serve on its Risk and Human Capital and Compensation Committees.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
13 May 2026
Axis Capital Declares Quarterly Dividends
Read ↗
seekingalpha.com
4 May 2026
Investment Qualities Of AXIS Capital's Preferred After The Company's Latest Report
Read ↗
seekingalpha.com
30 Apr 2026
AXIS Capital Holdings Limited (AXS) Q1 2026 Earnings Call Transcript
Read ↗
globenewswire.com
29 Apr 2026
Axis Capital Reports First Quarter Net Income Available to Common Shareholders of $247 Million, or $3.29 Per Diluted Common Share and Operating Income of $257 Million, or $3.42 Per Diluted Common Share
Read ↗
zacks.com
29 Jun 2026
Strength Seen in Axis Capital (AXS): Can Its 3.9% Jump Turn into More Strength?
Read ↗
zacks.com
26 Jun 2026
AXS Outperforms Industry, Trades Near 52-Week High: Time to Exit?
Read ↗
Earnings news

AXS earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
globenewswire.com15 Jul 2026

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

2
globenewswire.com6 Jul 2026

AXIS Capital to Release Second Quarter Financial Results on July 28, 2026

PEMBROKE, Bermuda, July 06, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the second quarter ended June 30, 2026 on Tuesday, July 28, 2026 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Matthew Kirk, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Wednesday, July 29, 2026 at 8:30 a.m.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your AXS research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.